Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia

Journal of Psychiatric Research

Volumn 47, Issue 11, 2013, Pages 1760-1765

  Zai, Clement C ^a   Tiwari, Arun K ^a   Mazzoco, Marina ^a,b   de Luca, Vincenzo ^a   Müller, Daniel J ^a,c   Shaikh, Sajid A ^a   Lohoff, Falk W ^d   Freeman, Natalie ^a   Voineskos, Aristotle N ^a   Potkin, Steven G ^e   Lieberman, Jeffrey A ^f,h   Meltzer, Herbert Y ^g,i   Remington, Gary ^a   Kennedy, James L ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h Columbia University and the New York State Psychiatric Institute ^*  (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Pharmacogenetics; Schizophrenia; Tardive dyskinesia; Vesicular monoamine transporter 2 (VMAT2 SLC18A2)

Indexed keywords

VESICULAR MONOAMINE TRANSPORTER 2;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ALLELE; ARTICLE; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE REPLICATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC CODE; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

(AIMS); (CATIE); (SNP); (TD); (VMAT2); ABNORMAL INVOLUNTARY MOVEMENT SCALE; CLINICAL ANTIPSYCHOTIC TRIALS OF INTERVENTION EFFECTIVENESS; PHARMACOGENETICS; SCHIZOPHRENIA; SINGLE-NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; VESICULAR MONOAMINE TRANSPORTER 2; VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2/SLC18A2);

ANALYSIS OF VARIANCE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MOVEMENT DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84884412527     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.07.025     Document Type: Article

References (53)

1. Aberg K., Adkins D.E., Bukszar J., Webb B.T., Caroff S.N., Miller del D., et al. Genomewide association study of movement-related adverse antipsychotic effects. Biological Psychiatry 2010, 67:279-282.
2. Abilio V., Vera J.J., Ferreira L., Duarte C., Martins C., Torres-Leite D., et al. Effects of melatonin on behavioral dopaminergic supersensitivity. Life Sciences 2003, 72:3003-3015.
3. Diagnostic and statistical manual of mental disorders 2000, APA, Washington, DC. 4th ed. - text revision.
4. Bakker P.R., van Harten P.N., van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Molecular Psychiatry 2008, 13:544-556.
5. Barrett J., Fry B., Maller J., Daly M. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
6. Basile V., Masellis M., Badri F., Paterson A., Meltzer H., Lieberman J., et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999, 21:17-27.
7. Calle M.L., Urrea V., Malats N., Van Steen K. mbmdr: an R package for exploring gene-gene interactions associated with binary or quantitative traits. Bioinformatics 2010, 26:2198-2199.
8. Chen J.J., Ondo W.G., Dashtipour K., Swope D.M. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clinical Therapeutics 2012, 34:1487-1504.
9. Cho C.H., Lee H.J. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Progress in Neuro-Psychopharmacology & Biological Psychiatry Oct 31 2012, 1-7.
10. Colantuoni C., Lipska B.K., Ye T., Hyde T.M., Tao R., Leek J.T., et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 2011, 478:519-523.
11. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Human Heredity 2008, 66:87-98.
12. Gauderman W.J., Morrison J.M. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies 2006.
13. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Annals of Clinical Psychiatry 2002, 14:47-57.
14. Gerlach J., Casey D. Tardive dyskinesia. Acta Psychiatrica Scandinavica 1988, 77:369-378.
15. Goumeniouk A.D. The importance of movement disorders with newer atypical antipsychotics. Canadian Journal of Diagnosis 2012, 1--12; Toronto: STA HealthCare Communications Inc.
16. Greenbaum L., Alkelai A., Zozulinsky P., Kohn Y., Lerer B. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics Journal 2012, 12(6):513-520.
17. Guy W. Abnormal involuntary movement scale. ECDEU assessment manual for psychopharmacology 1976, 534-537. Department of Health Education and Welfare, Washington DC. Revised ed.
18. Inada T., Koga M., Ishiguro H., Horiuchi Y., Syu A., Yoshio T., et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenetics and Genomics 2008, 18(4):317-323.
19. Jeste D. Tardive dyskinesia in older patients. Journal of Clinical Psychiatry 2000, 61(Suppl.4):27-32.
20. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry 1996, 153:466-476.
21. Klawans H., Goetz C., Perlik S. Tardive dyskinesia: review and update. American Journal of Psychiatry 1980, 137:900-908.
22. Lee H.J., Kang S.G. Genetics of tardive dyskinesia. International Review of Neurobiology 2011, 98:231-264.
23. Lerer B., Segman R., Tan E.-C., Basile V., Cavallaro R., Aschauer H., et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. International Journal of Neuropsychopharmacology 2005, 8:411-425.
24. Li J., Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005, 95:221-227.
25. Lohr J., Kuczenski R., Niculescu A. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17(1):47-62.
26. Margolese H.C., Chouinard G., Kolivakis T.T., Beauclair L., Miller R., Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Canadian Journal of Psychiatry 2005, 50:703-714.
27. Marsalek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000, 33(S1):14-33.
28. Müller D., Schulze T., Knapp M., Held T., Krauss H., Weber T., et al. Familial occurrence of tardive dyskinesia. Acta Psychiatrica Scandinavica 2001, 104:375-379.
29. Müller D., Shinkai T., De Luca V., Kennedy J. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics Journal 2004, 4:77-87.
30. Muller D.J., Chowdhury N.I., Zai C.C. The pharmacogenetics of antipsychotic-induced adverse events. Current Opinion in Psychiatry 2013, 26:144-150.
31. Nyholt D. Asimple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. American Journal of Human Genetics 2004, 74:765-769.
32. Ondo W.G., Hanna P.A., Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. American Journal of Psychiatry 1999, 156:1279-1281.
33. Rilstone J.J., Alkhater R.A., Minassian B.A. Brain dopamine-serotonin vesicular transport disease and its treatment. New England Journal of Medicine 2013, 368:543-550.
34. Roe B.E., Tilley M.R., Gu H.H., Beversdorf D.Q., Sadee W., Haab T.C., et al. Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) gene. PLoS One 2009, 4. e6704.
35. Schooler N., Kane J. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 1982, 39(4):486-487.
36. Schwab S.G., Franke P.E., Hoefgen B., Guttenthaler V., Lichtermann D., Trixler M., et al. Association of DNA polymorphisms in the synaptic vesicular amine transporter gene (SLC18A2) with alcohol and nicotine dependence. Neuropsychopharmacology 2005, 30:2263-2268.
37. Shinkai T., Müller D., De Luca V., Shaikh S., Matsumoto C., Hwang R., et al. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Research 2006, 141:123-128.
38. Simons C.J., van Winkel R. Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition. Schizophrenia Bulletin 2013, 39(4):848-856.
39. Syu A., Ishiguro H., Inada T., Horiuchi Y., Tanaka S., Ishikawa M., et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacology 2010, 35:1155-1164.
40. Talkowski M.E., Kirov G., Bamne M., Georgieva L., Torres G., Mansour H., et al. Anetwork of dopaminergic gene variations implicated as risk factors for schizophrenia. Human Molecular Genetics 2008, 17:747-758.
41. Tamminga C.A., Thaker G.K., Chase T.N. GABA dysfunction in the pathophysiology of tardive dyskinesia. Psychopharmacology Supplementum 1985, 2:122-127.
42. Tanaka S., Syu A., Ishiguro H., Inada T., Horiuchi Y., Ishikawa M., et al. DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia. Pharmacogenomics Journal 2013, 13(1):27-34.
43. Tarsy D., Baldessarini R. The pathophysiologic basis of tardive dyskinesia. Biological Psychiatry 1977, 12:431-450.
44. Tarsy D., Baldessarini R. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?. Movement Disorders 2006, 21(5):589-598.
45. Tritsch N.X., Ding J.B., Sabatini B.L. Dopaminergic neurons inhibit striatal output through non-canonical release of GABA. Nature 2012, 490:262-266.
46. Tsai H.T., Caroff S.N., Miller del D., McEvoy J., Lieberman J.A., North K.E., et al. Acandidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : The Official Publication of the International Society of Psychiatric Genetics 2010, 153B:336-340.
47. Zai C., DeLuca V., Hwang R., Voineskos A., Müller D., Remington G., et al. Meta-analysis of two Dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Molecular Psychiatry 2007, 12(9):794-795.
48. Zai C., Hwang R., De Luca V., Müller D., King N., Zai G., et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2007, 10(5):639-651.
49. Zai C., Romano-Silva M., Hwang R., Zai G., deLuca V., Müller D., et al. Genetic study of eight AKT1 Gene polymorphisms and their interaction with DRD2 Gene polymorphisms in tardive dyskinesia. Schizophrenia Research 2008, 106(2-3):248-252.
50. Zai C., Tiwari A., deLuca V., Müller D., Hwang R., Zai G., et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. European Neuropsychopharmacology 2009, 19(5):317-328.
51. Zai C.C., Tiwari A.K., Basile V., De Luca V., Müller D.J., King N., et al. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J 2009, 9(3):168-174.
52. Zai C.C., Tiwari A.K., Basile V., de Luca V., Muller D.J., Voineskos A.N., et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34:50-56.
53. Zai C.C., Tiwari A.K., Muller D.J., De Luca V., Shinkai T., Shaikh S., et al. The catechol-O-methyl-transferase gene in tardive dyskinesia. World Journal of Biological Psychiatry 2010, 11:803-812.